![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/spacer.gif)
PGLA/PEG copolymer-based paclitaxel A controlled-release, intratumoral paclitaxel formulation in which paclitaxel is incorporated into a thermosensitive, biodegradable triblock copolymer consisting of poly(lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG). Upon intratumoral injection, paclitaxel is released slowly and continuously into tumor tissues from the gelled thermosensitive triblock copolymer over a period of 4 to 6 weeks; in tumor cells, paclitaxel binds to tubulin and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. The thermosensitive triblock copolymer component of this formulation transforms from a water-soluble polymer at room temperature to a water-insoluble, biodegradable gel depot at body temperature; intratumoral controlled-release of paclitaxel from the gel minimizes systemic exposure to paclitaxel and the paclitaxel toxicity profile. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/spacer.gif) | OncoGel | | ![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090114225839im_/http://www.cancer.gov/images/spacer.gif) |